Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease.

By Rik Ossenkoppele, D. Schonhaut, Michael Schöll, Samuel N. Lockhart, Nagehan Ayakta, Suzanne L. Baker, James P. O'Neil, Mustafa Janabi, Andreas Lazaris, Averill Cantwell and 10 more. Brain : a journal of neurology, 2016

1,084 citations recorded by the source corpus.

Subfields: Cognitive Neuroscience, Physiology, Psychiatry and Mental health

View Paper: https://www.semanticscholar.org/paper/f467b3da0ef69d35f2a1f5761baceb0418f7ad55

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cognitive Neuroscience

1. Bruce L. Miller
2. Suzanne L. Baker
3. William J. Jagust
4. Gil D. Rabinovici
5. Joel H. Kramer
6. A. Maass

In Physiology

1. Guy C. Brown
2. Michael Coleman
3. Bruce L. Miller
4. Suzanne L. Baker
5. William J. Jagust
6. Gil D. Rabinovici
7. Susan M. Landau
8. Andy Horng

In Psychiatry and Mental health

1. Bruce L. Miller
2. Suzanne L. Baker
3. William J. Jagust
4. Gil D. Rabinovici
5. Samuel N. Lockhart

Citations in the corpus

• Microglia in Neurological Diseases: A Road Map to Brain-Disease Dependent-Inflammatory Response (2018, background): “This has been linked to neurodegeneration and cognitive impairment (Ossenkoppele et al., 2016; Bejanin et al., 2017).”
• Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer’s disease (2017, background): “Alzheimer’s disease individuals (Cho et al., 2016b; Ossenkoppele et al., 2016; Schöll et al., 2016) by including”
• Neuronal Cell Death. (2018, positive): “In AD, recent advances in PET imaging have allowed a glimpse into the prevalence and distribution of amyloid plaques and NFT in individuals, and mapping the advancement of the disease using longitudinal measures (349, 365, 527, 603, 614, 709).”
• Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease (2017, background): “Together these findings are in line with previous observations by Ossenkoppele et al. (2016); overlapping data set) that greater AV-1451 uptake in neocortical regions is associated with younger age-of-onset and non-amnestic clinical presentations of AD patients, while greater medial temporal lobe…”